Objective: To determine whether extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among incarcerated individuals with HIV and alcohol use disorders (AUDs) transitioning to the community.
INTRODUCTION
Globally, people living with HIV (PLH), and especially those with substance use disorders, are disproportionately concentrated in prisons and jails. 1 In the United States (US), one-sixth of the 1.2 million PLH cycle through these criminal justice settings annually, resulting in an HIV prevalence that is 3-fold higher than the community. 2 Despite high levels of viral suppression (VS) achieved during incarceration, 3 this transition is made tumultuous by low linkage to HIV care, 4 high rates of relapse to substance use, 5 homelessness, 6 and overdose. 7 Together, these factors undermine adherence to antiretroviral therapy (ART) after release and result in loss of VS. 4, [8] [9] [10] Alcohol use disorders (AUDs) are 8 times more prevalent in criminal justice populations than in the community, with relapse especially common and problematic after release. 11, 12 In PLH, AUDs exacerbate ART nonadherence, resulting in suboptimal VS. 13 Most prisoners in the United States do not receive medication to treat AUDs or prevent relapse to alcohol use at the time of release. 11, 14 Extendedrelease naltrexone (XR-NTX) is an evidence-based and Food and Drug Administration-approved treatment for AUDs, which delays and reduces alcohol consumption, 15 including for incarcerated PLH with AUDs and released to the community. 16 We therefore hypothesized that XR-NTX would reduce alcohol consumption in PLH with AUDs who are transitioning to the community and either maintain or improve VS after release, compared with those with untreated AUDs. We tested this hypothesis within a placebo-controlled trial using XR-NTX by specifically examining the influence of XR-NTX on achieving VS 6 months after release from prison or jail.
METHODS
A double-blind, placebo-controlled prospective trial of XR-NTX among PLH with AUDs who were transitioning to the community was conducted from September 2010 through February 2016 in 2 sites in Connecticut. Eligible participants were randomized 2:1 to XR-NTX or placebo, receiving their first injection within 1 week before release from prison or jail; treatment was continued for 6 months after release. Recruitment procedures and eligibility criteria, 17 early and final retention levels, [16] [17] [18] hepatic safety, 16, 19 alcohol consumption outcomes, 16 and adverse events 16 have previously been reported.
Recruitment
After screening, 100 participants were ultimately recruited from prisons and jails within the Connecticut Department of Correction. Incarcerated PLH were first screened for self-reported hazardous drinking ($4 drinks daily for women or $5 drinks daily for men), 20 followed by more detailed screening assessments. 17 Screening, Eligibility, and Consent Inclusion Criteria
(1) Documented HIV-infection; (2) adults aged 18 years and older; (3) transitioning to either New Haven or Hartford, Connecticut; (4) met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for alcohol abuse or dependence using the Mini International Neuropsychiatric Interview 21 or hazardous drinking using the Alcohol Use Disorders Identification Test (score $4 for women and $8 for men) 22 ; (5) provided informed consent; and (6) spoke English or Spanish.
Exclusion Criteria
(1) Prescribed opioid pain medications or reported a medical indication for them after release; (2) grade 3 or higher aspartate aminotransferase or alanine aminotransferase elevations (.5· upper limit of normal); (3) evidence of Childs-Pugh class C cirrhosis; (4) enrolled in another alcohol pharmacological or ART adherence study; or (5) breastfeeding, pregnant, or unwilling to use contraception (women only).
Eligible and interested prisoners then completed verbal and written informed consent procedures, which were repeated immediately after release to prevent real or perceived coercion.
Ethical Oversight
All study procedures were reviewed and approved by the institutional review board at Yale University, the Connecticut Department of Correction Research Advisory Committee, and the Office of Human Research Protections. A Certificate of Confidentiality was obtained from the National Institutes of Health. The study is registered at www. clinicaltrials.gov (NCT01077310).
Randomization
After consent, participants were randomly assigned 2:1 to receive 380 mg of XR-NTX (Vivitrol) or placebo (provided in-kind by Alkermes, Inc., Waltham, MA), administered intramuscularly every 4 weeks for 6 months. A covariate-adapted stratified block randomization was performed controlling for the presence or absence of concurrent opioid use disorder and whether prescribed ART or not. 17 
Study Measures
HIV-1 RNA levels, along with CD4 T-lymphocyte cell counts, were assessed at baseline, time of release, and at 3 and 6 months after release. Other study measures included demographic information (age, sex, race, and housing status), type of ART regimen (protease inhibitor, non-nucleoside reverse transcriptase inhibitor, or integrase strand transfer inhibitor regimens), health insurance status, duration of incarceration, symptoms of depression using the Brief Symptom Inventory (defined as a general T-score of $63 or any 2 primary dimension scores of $63), 23 alcohol and drug use, hepatitis C virus coinfection, and presence of comorbid mental illness and other substance use disorders using the Mini International Neuropsychiatric Interview. Our alcohol consumption variables 16 were derived from a timeline follow-back 24, 25 that assessed self-reported daily totals of standard drinking units before incarceration and monthly for 6 months. Because drinking patterns are varied, we used a previously described alcohol improvement score to more comprehensively measure heterogeneous drinking patterns. 16 This score included the (1) time to first heavy drinking day; (2) total number of drinks per drinking day; (3) percent of heavy drinking days ($5 drinks per day for men or $4 drinks per day for women); (4) preincarceration to postincarceration change in average drinks per day; and (5) total number of drinking days. Each of these 5 variables were combined and weighted equally with a score of "1" for favorable outcomes and combined into a unit-weighted composite score using previously described criteria. 16 This score generated a single summary measure that was more easily amenable to interpretation of heterogeneous drinking patterns and more sensitive to data variance and subtle changes by reducing floor and ceiling effects. 16 Adverse events were also monitored monthly and included hepatic transaminase levels and injection site reactions. Previous reports from this trial found no differences in adverse events between the 2 groups nor were there any serious adverse events in either treatment group. 16 
Outcome Variables
The original preplanned primary outcomes were defined as the proportion that achieved or maintained HIV VS at the ,400 and the ,50 copies per milliliter levels from baseline to 6 months. The Department of Health and Human Services HIV treatment guidelines changed their definition of VS to ,200 copies per milliliter as the goal of therapy soon after study initiation, 26 resulting in a change in one of the primary outcomes from ,400 to ,200 copies per milliliter. 17 The other preplanned coprimary outcome, change in maximal VS defined as ,50 copies per milliliter, remained a clinically important outcome in real-world practice and is listed as a secondary outcome in this article. Using an intention-to-treat (ITT) strategy, the primary and secondary outcomes involved a comparison of the changes in VS levels of ,200 and ,50 copies per milliliter from baseline to 6 months after release in both treatment groups, respectively. This outcome best reflected how participants did over time (baseline to 6 months) because our hypothesis was that participants who received placebo would be more likely to lose VS after release, whereas those who benefited from XR-NTX would either maintain or improve VS levels, or if not on ART, initiate it because of increased postrelease stability. 27, 28 In addition, the difference between groups in proportions with VS at the 6-month time point was assessed.
Sample Size and Power Calculations
We calculated an original sample size of 125 (XR-NTX = 83 and placebo = 42) needed to detect a statistically significant difference in the primary outcome at 6 months between the 2 groups. This incorporated a 2-sided alpha = 0.05, beta = 0.20, and a compound symmetry true correlation structure of 0.5 (the most conservative, based on our results from earlier studies where our prison-release data suggested that 59% of HIV+ inmates leave prison with VS, 10 and where 28% of HIV prisoners with an AUD leaving prison have VS after 6 months). 29 Power calculations, as previously published, 17 also included oversampling (2:1 randomization) those receiving XR-NTX due to concern for potential increase in adverse events 30 in the XR-NTX group and were also based on aforementioned studies of released prisoners who had 80% retention after 6 months. 29, 31 Participants' Disposition Of the 195 PLH referred to the study, 118 consented and completed baseline interviews, and 100 were fully reenrolled and randomized and included in the final analytical sample; 67 were randomized to receive XR-NTX and 33 to receive placebo. The CONSORT diagram is depicted in Figure 1 . Study retention was not statistically different between study arms as reported in a previous article. 16 
Analytical Approach Missingness Analysis
Overall, 13% of participants who were randomized had missing HIV-1 RNA data 6 months after release. Therefore, we explored the structure of the missing data to determine whether the data were "missing completely at random" (MCAR) and not related to the dependent or independent variables. The structure of the missing data was assessed using the Little MCAR 32 test implemented with code within the BaylorEdPsych package in R software. 33 The highly nonsignificant results for the Little MCAR test (P = 0.560) suggested that the missing data were not statistically related to the main outcome (VS), viral load at baseline, nor any of the variables used in the analysis, most importantly, treatment assignment or number of XR-NTX injections. High P values for the Little MCAR test also suggested that further missingness inquiries using sensitivity analysis were not merited because the data were clearly neither missing at random nor not missing at random. 34, 35 Although the MCAR result allowed for the application of multiple imputation, when this was performed, it gave inconsistent results because of colinearity of some variables. Consequently, we were able to maintain the most conservative standard ITT assumption that missingness from participant attrition equals viral nonsuppression (missing = failure). This is the standard analytic method for regulatory submission of HIV-1 RNA data to the US Food and Drug Administration, 36 which provides the most sensitive and conservative detection limits available and used previously in prospective trials of PLH where HIV-1 RNA is the outcome.
Intention to Treat Analysis of Viral Suppression From Baseline to 6 Months After release
An ITT analysis was conducted first by dichotomizing VS as suppressed or nonsuppressed, and comparing VS levels for primary and secondary outcomes at 6 months was performed using x 2 testing. Furthermore, change in VS over time from baseline to 6 months was deployed to more accurately reflect the differences in VS levels. These analyses were conducted using T tests in R statistical software.
Multiple Logistic Regression Analysis of Predictors of Viral Suppression at 6 Months
After confirming that a statistically significant difference was found for each level of VS both over time and at 6 months, we explored predictive variables guided by the literature that included receipt of ART, 9,18 as well as specific to this study, treatment assignment, and the number of injections received, to further explain independent predictors for the primary (VS ,200 copies/mL) and secondary (VS ,50 copies/mL) outcomes. Of note, most participants were receiving ART, and there was no difference in the number on ART with almost 90% receiving ART at the time of release. The number of injections was dichotomized as 2 or fewer injections vs. 3 or more to reflect better retention in the study because of previous studies showing that the first 3 months is enough time to lose VS after release. 8, 10 A backward stepwise model selection "step" algorithm in R software then sequentially eliminated variables until we achieved models with the best goodness-of-fit using the Akaike information criterion (AIC) because they yielded the most parsimonious results. Of note, because of the number of potential variables, those with the best AIC are demonstrated.
RESULTS

Baseline Characteristics
The baseline characteristics are described in Table 1 . Participants were on average in their mid-40s, mostly men (77%), racial/ethnic minorities (84%), homeless or unstably housed (63%), and prescribed ART (87%) and had major depression (75%). Central to the analysis, baseline VS levels at ,200 and ,50 copies per milliliter were 53% and 35%, respectively, and not significantly different (66% had VS , 400 copies/mL and not significantly different). The 2 treatment arms did not differ significantly for any baseline variable aside from median CD4 count (XR-NTX: 490 vs. placebo: 418 cells/mL; P = 0.033); however, 90% of participants in both groups had CD4 counts .200 cells/mL.
Intention to Treat Analysis: Comparison of Viral Suppression at Baseline and 6 Months After release Figure 2 depicts the change in VS levels from baseline to 6 months after release using the ITT analysis in each treatment group and the between-group differences at the 6-month time point for both outcomes. At baseline as previously mentioned, there were no differences in VS levels for either the primary or secondary VS outcome as shown in Table 1 . The primary VS outcome (,200 copies/mL) did not statistically significantly improve from baseline (64%) to 6 months (42.4%) for the placebo group (P = 0.070) nor did it for the secondary VS outcome (,50 copies/mL) (42.0% to 30.3%, P = 0.292); VS ,400 copies/mL also did not improve for the placebo group from baseline (66.7%) to 6 months (42.4%, P = 0.030). The XR-NTX group significantly improved from baseline to 6 months for the primary VS outcome (,200 copies/mL) (48.0% to 64.2%, P = 0.024) and for the secondary VS outcome (,50 copies/mL) (31.0% to 56.7%, P = 0.001); VS ,400 copies/mL in the XR-NTX group was maintained from baseline (63.6%) to 6 months (53.7%, P = 0.260). Furthermore, at 6 months, compared with placebo, participants who received XR-NTX were also significantly more likely to have VS for both the primary (,200 copies/mL) (64.2% XR-NTX vs. 42.4% placebo; P = 0.041) and secondary VS outcomes (,50 copies/mL) (56.7% XR-NTX vs. 30.3% placebo; P = 0.015). VS ,400 copies/mL at 6 months was not significantly different between groups (53.7% XR-NTX vs. 42.2% placebo, P = 0.289). Of note, additional analyses found that no participants in the placebo group who were not on ART at baseline achieved VS, whereas 14.3% of those not on ART at baseline in the XR-NTX group did achieve VS at that level at the 6-month time point. 
Independent Predictors of Achieving VS
The independent correlates of achieving VS for the primary and secondary outcomes are provided in Table 2 . For the primary outcome (VS ,200 copies/mL), both allocation to receive XR-NTX [adjusted odds ratio (aOR): 2.68; 95% confidence interval = 1.01 to 7.09] and receipt of 3 or more injections (aOR: 3.26; 95% confidence interval = 1.26 to 8.47), irrespective of allocation, predicted VS at ,200 copies per milliliter. Treatment allocation to XR-NTX, receiving 3 or more injections, decreasing levels of alcohol consumption using the alcohol improvement score, and white racepredicted maximal VS (,50 copies/mL). Additional multivariate analyses (not shown) compared (1) those in the XR-NTX group who received 3 or more injections compared with (2) the XR-NTX group who received 2 or fewer injections plus all placebo participants. A second multivariate model was created placing (1) all the placebo participants who had received 3 or more injections against (2) participants who received placebo with 2 injections and fewer and all XR-NTX participants. In the first model, the XR-NTX with 3 or more injections was significantly related to VS (,50 copies/ mL level; P # 0.05), whereas the second model was not significantly different for high injection placebo participants. Of note, as shown in Table 2 , concurrent opioid use disorder diagnosis was not found to be associated with explaining the difference in VS at either the ,200 copies per milliliter (P = 0.241) or ,50 copies per milliliter outcomes (0.645).
DISCUSSION
To the best of our knowledge, this is the first doubleblind, placebo-controlled prospective randomized trial that examines whether an evidence-based pharmacotherapy to treat AUDs, XR-NTX, influences HIV viral suppression in PLH with AUDs who are transitioning to the community from prison or jail. The key findings from this trial, using an ITT analysis with the most conservative assessments for missing data, support that both VS (,200 copies/mL) and maximal VS (,50 copies/mL) are more likely to be achieved in PLH receiving XR-NTX than in those receiving placebo. These findings support the use of XR-NTX in PLH with AUDs who are transitioning through prisons and jails, an intervention that may improve linkage to HIV care and promote VS. This is especially important given that as few as 21% and 34% of PLH in Connecticut prisons and jails are linked to HIV care within 14 and 30 days after release to the community, respectively, 4 the minimal time needed to get their ART prescriptions refilled.
To support the ITT findings, multiple logistic regression analyses provide further support for XR-NTX, and provide additional insights and interpretation of the data. Key among them is that receiving more XR-NTX injections results in improved HIV VS levels. This suggests that better retention on the intervention (ie, monthly injections) was highly correlated with better engagement in HIV treatment and adherence to ART. This is consistent with findings that patients consistently engaged in care have higher levels of VS. 37, 38 For maximal VS (,50 copies/mL), 2 additional factors contributed to the outcome-reductions in alcohol consumption and white race. Although considerable health disparities by race/ethnicity persist in the United States, especially among prisoners and PLH, 39-43 recent studies have not found that race/ethnicity predicts linkage to HIV care after release. 4 Reductions in alcohol consumption were significantly predictive of maximal VS (,50 copies/mL) and approached significance (P = 0.068) for the primary VS outcome (,200 copies/mL). One explanation for these findings may be that previous data suggest that the number of days of alcohol consumption is associated with missing ART doses, not only on drinking days but also for 2 days after consumption. 44 Thus, maximal VS (,50 copies/mL) may have been better achieved because of better reductions in alcohol consumption, which in turn, reduced the number of days that patients missed taking their ART. Of note, most participants, almost 90%, were already receiving ART at the time of randomization (baseline or time of release), and there were no significant differences between the groups in those receiving ART. In addition, at 6 months, we found that no participants in the placebo group who were not on ART at baseline achieved VS at the ,50 copies per milliliter level, whereas 14.3% of those in the XR-NTX who were not on ART at baseline group did achieve VS at that level at the 6-month time point, suggesting that possibly XR-NTX through reductions in alcohol use also may have assisted in initiating ART. Thus the combination of ART with reductions in alcohol use through the use of a medication (XR-NTX) to reduce alcohol relapse can improve the likelihood of maintaining or achieving HIV VS. Although the effect of XR-NTX on VS is likely moderated by reductions in alcohol consumption thereby improving adherence to ART, further research is needed to determine whether these beneficial effects are either fully or partially mediated by antiviral or anti-inflammatory mechanisms. [45] [46] [47] Findings from this study have important implications for both individual and public health. Given the magnitude of PLH and AUDs who cycle through US prisons and jails annually the and paucity of associated prescribed medications to reduce alcohol relapse before, during, or after incarceration, 11 these findings suggest that XR-NTX may help PLH with AUDs remain in HIV care and achieve VS after release. XR-NTX, if implemented properly, may markedly improve postrelease HIV treatment outcomes. Whether or not these findings can be extended to others in confined settings such as hospitals or addiction treatment programs must be further examined. These findings do, however, have important implications for HIV treatment guidelines. Presently, the International Association of Physicians in AIDS Care (IA-PAC) ART adherence guidelines 48 for criminal justice populations transitioning to the community recommend (1) directly administered antiretroviral treatment (DAART) for released prisoners at high risk of ART nonadherence and for people who inject drugs and (2) treatment of opioid use disorders with opioid agonist therapies such as methadone or buprenorphine. 48 Findings here should extend these recommendations to include the use of XR-NTX for treatment of AUDs in eligible PLH transitioning from incarceration. Improved adherence with XR-NTX will likely reduce the need for DAART in this population.
The 90-90-90 Joint United Nations Programme on HIV/ AIDS (UNAIDS) strategy 49 in the United States has nearly achieved its first step-HIV diagnosis. Engagement in care and VS, however, fall considerably short. Because XR-NTX seems to exert its influence both on better treatment engagement/retention, but also on VS levels, it can potentially improve both individual health and "treatment as prevention" ideals through higher VS levels. This is especially true in incarcerated PLH with AUDs who engage in high-risk HIV behaviors after release and in whom higher VS levels may be translated into reduced transmission. One of the major impediments of adoption and implementation of an evidence-based treatment for prisoners involves cost. The strongest evidence to improve VS levels for transitioning incarcerated individuals is DAART, 50 yet it is rarely implemented because of limited community resources and elevated costs. 48 Although pharmacotherapy using methadone or buprenorphine for transitioning incarcerated individuals with HIV and opioid use disorder is recommended and is associated with low cost; 27 XR-NTX, however, remains costly. A recently published randomized placebocontrolled trial found that XR-NTX also led to improved VS for incarcerated individuals released to the community with HIV and opioid use disorders. 51 Findings from this trial provide the highest level of support for treating AUDs in transitioning incarcerated individuals with HIV and pending cost-effectiveness analyses; it should be adopted as voluntary treatment of AUDs as part of the US response to controlling the HIV pandemic.
Despite the many new and important findings presented here, some limitations remain, including the sample size and lack of generalizability to other communities. Poor retention in clinical care, including missing follow-up data from research studies after release from criminal justice settings, is common. 6, 10 In this study, missing follow-up data were low (13%), but the MCAR analysis allowed us to use the most conservative assumption for comparing VS with missing observations for HIV-1 RNA levels being treated as not achieving VS. This limitation, however, is typically what is considered in real-world treatment settings of PLH where the association between poor retention, particularly missed visits, and poorer biological outcomes evidenced by virological failure and mortality is well established in the literature. 37, 38 Using a missing value as "failure" to achieve VS is the most conservative strategy for not achieving or maintaining VS. Despite some missingness of viral load data and the relatively small sample size, the findings remain robust even controlling for other factors. Moreover, although including persons with mental illness and polysubstance use likely contributed to elevated attrition levels as seen in this study, 16, 18 these results are more reflective of the real-world effectiveness of XR-NTX as a community-based treatment.
CONCLUSIONS
Monthly administered XR-NTX is an effective strategy to reduce alcohol consumption in PLH with AUDs transitioning to the community from prisons and jails. This study extends the benefits of XR-NTX as a treatment for AUDs and supports the additional benefit it has on improving HIV treatment outcomes in combination with ART in this population, specifically the achievement and maintenance of VS and maximal VS, the cornerstone of individual and public health for PLH. This study is the first to demonstrate the multifaceted benefits of XR-NTX in this vulnerable population of incarcerated persons with HIV and AUDs and adds to the important recent findings of XR-NTX improving VS among incarcerated persons with HIV and opioid use disorder. 51 Newer longer-acting naltrexone preparations, including implantable naltrexone that lasts for 3-6 months, might overcome challenges with returning for monthly injections. Also, although the cost of XR-NTX remains high, one must balance the costs with the societal benefits. Realworld implementation studies are needed to examine its effectiveness. Future work should evaluate costeffectiveness of XR-NTX in incarcerated individuals transitioning to the community as well as in other community settings where HIV and AUDs are highly prevalent to assess the generalizability of this strategy to improve VS and further, to examine its impact on treatment as prevention efforts.
